Fluvoxamine-a New Serotonin Re-uptake Inhibitor: First Clinical and Psychometric Experiences in Depressed Patients

Overview

Journal J Neural Transm

Specialties Neurology
Physiology

Date 1977 Jan 1

PMID 335026

Citations 14

Authors

B Saletu

M Schjerve

J Grunberger

H Schanda

O H Arnold

Affiliations

Soon will be listed here.

Abstract

The clinical efficacy of fluvoxamine (DU 23000)--the first selective serotonin re-uptake inhibitor of the new class of 2-aminoethyloximethers of aralkylketones was investigated in endormorphous depressed patients during 5 weeks treatment with mean daily dosages of approximately 150 mg DU 23000. A marked and statistically significant improvement of the overall and detailed psychopathology was noted by means of the Global Clinical Impression and Hamilton Rating Scale as early as in the first week of drug administration. Bipolar patients tended to improve more than unipolar ones, retarded depressions more than agitated ones. An additional anxiolytic medication was occasionally required. The drug was well tolerated. Psychometric and laboratory findings did not show any significant changes. The findings are discussed in the light of the indolamine hypothesis of depression.

Citing Articles

Therapeutically targeting the consequences of HIV-1-associated gastrointestinal dysbiosis: Implications for neurocognitive and affective alterations.

Rodriguez M, McLaurin K, Shtutman M, Kubinak J, Mactutus C, Booze R Pharmacol Biochem Behav. 2023; 229:173592.

PMID: 37390973 PMC: 10494709. DOI: 10.1016/j.pbb.2023.173592.

Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19).

McCarthy M Expert Opin Pharmacother. 2022; 23(5):623-628.

PMID: 35103549 PMC: 8862166. DOI: 10.1080/14656566.2022.2035360.

Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Wilde M, Plosker G, Benfield P Drugs. 1993; 46(5):895-924.

PMID: 7507038 DOI: 10.2165/00003495-199346050-00008.

A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers.

Robinson J, Doogan D Br J Clin Pharmacol. 1982; 14(6):805-8.

PMID: 6817771 PMC: 1427539. DOI: 10.1111/j.1365-2125.1982.tb02040.x.

Clovoxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting antidepressants: quantitative EEG, psychometric and pharmacokinetic studies in man.

Saletu B, Grunberger J, Rajna P, Karobath M J Neural Transm. 1980; 49(1-2):63-86.

PMID: 6777458 DOI: 10.1007/BF01249190.

References

Bourne H, Bunney Jr W, Colburn R, Davis J, Davis J, Shaw D . Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients. Lancet. 1968; 2(7572):805-8. DOI: 10.1016/s0140-6736(68)92459-8. View

van Praag H, Korf J, Dols L, SCHUT T . A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as antidepressant. Psychopharmacologia. 1972; 25(1):14-21. DOI: 10.1007/BF00422612. View

Coppen A, Prange Jr A, Whybrow P, Noguera R . Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry. 1972; 26(5):474-8. DOI: 10.1001/archpsyc.1972.01750230084016. View

Sarai K, Kayano M . The level and diurnal rhythm of serum serotonin in manic-depressive patients. Folia Psychiatr Neurol Jpn. 1968; 22(3):271-81. DOI: 10.1111/j.1440-1819.1968.tb01425.x. View

Schildkraut J . Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: preliminary findings. Am J Psychiatry. 1973; 130(6):695-9. DOI: 10.1176/ajp.130.6.695. View

Schildkraut J, Keeler B, Papousek M, Hartmann E . MHPG excretion in depressive disorders: relation to clinical subtypes and desynchronized sleep. Science. 1973; 181(4101):762-4. DOI: 10.1126/science.181.4101.762. View

GREENSPAN K, Schildkraut J, Gordon E, Baer L, Aronoff M, Durell J . Catecholamine metabolism in affective disorders. 3. MHPG and other catecholamine metabolites in patients treated with lithium carbonate. J Psychiatr Res. 1970; 7(3):171-83. DOI: 10.1016/0022-3956(70)90004-x. View

Cochran E, Robins E, Grote S . Regional serotonin levels in brain: a comparison of depressive suicides and alcoholic suicides with controls. Biol Psychiatry. 1976; 11(3):283-94. View

van Praag H, Korf J, Puite J . 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature. 1970; 225(5239):1259-60. DOI: 10.1038/2251259b0. View

10.

MENDELS J, Stinnett J, Burns D, Frazer A . Amine precursors and depression. Arch Gen Psychiatry. 1975; 32(1):22-30. DOI: 10.1001/archpsyc.1975.01760190024002. View

11.

Saletu B . [Psychotropic drugs, brain function and sleep. Neurophysiologic aspects of psychopharmacology and pharmacopsychiatry]. Bibl Psychiatr. 1976; (155):1-245. View

12.

VAN PRAAGH , Leijnse B . [THE SIGNIFICANCE OF MONOAMINE OXIDASE INHIBITION AS AN ANTIDEPRESSIVE PRINCIPLE. I]. Psychopharmacologia. 1963; 4:1-14. DOI: 10.1007/BF00429359. View

13.

JONES F, Maas J, Dekirmenjian H, Fawcett J . Urinary catecholamine metabolites during behavioral changes in a patient with manic-depressive cycles. Science. 1973; 179(4070):300-2. DOI: 10.1126/science.179.4070.300. View

14.

Korf J, van Praag H . Endogenous depressions with and without disturbances in the 5-hydroxytryptamine metabolism: A biochemical classification?. Psychopharmacologia. 1971; 19(2):148-52. DOI: 10.1007/BF00402638. View

15.

Beckmann H, Goodwin F . Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline. Arch Gen Psychiatry. 1975; 32(1):17-21. DOI: 10.1001/archpsyc.1975.01760190019001. View

16.

Murphy D, Baker M, Goodwin F, Miller H, Kotin J, Bunney Jr W . L-tryptophan in affective disorders: indoleamine changes and differential clinical effects. Psychopharmacologia. 1974; 34(1):11-20. DOI: 10.1007/BF00421216. View

17.

FOTHERBY K, Ashcroft G, AFFLECT J, Forrest A . Studies on sodium transfer and 5-hydroxyindoles in depressive illness. J Neurol Neurosurg Psychiatry. 1963; 26:71-3. PMC: 495538. DOI: 10.1136/jnnp.26.1.71. View

18.

Saletu B, Krieger P, Grunberger J, Schanda H, SLETTEN I . Tandamine--a new norepinephrine reuptake inhibitor. Clinical, psychometric and quantitative EEG studies in depressed patients. Int Pharmacopsychiatry. 1977; 12(3):137-52. View

19.

van Praag H, Korf J, Schut D . Cerebral monoamines and depression. An investigation with the Probenecid technique. Arch Gen Psychiatry. 1973; 28(6):827-31. DOI: 10.1001/archpsyc.1973.01750360053007. View

20.

Maas J, Fawcett J, Dekirmenjian H . Catecholamine metabolism, depressive illness, and drug response. Arch Gen Psychiatry. 1972; 26(3):252-62. DOI: 10.1001/archpsyc.1972.01750210060012. View